Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Acq. announced
Appointed COO
Quarterly results
Director departure
Appointed director
CC transcript
SYNAGEVA BIOPHARMA CORP (GEVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/23/2015 8-K Form 8-K - Current report
05/06/2015 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Agreement and Plan of Reorganization, among Alexion Pharmaceuticals, Inc., Pulsar Merger Sub Inc., Galaxy Merger Sub LLC and Synageva BioPharma Corp. Schedules to the Agreement and Plan of Reorganization have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request",
"Third Amended and Restated Bylaws of Synageva BioPharma Corp. (marked)",
"Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases"
04/29/2015 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATES"
02/26/2015 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA REPORTS 2014 FULL YEAR FINANCIAL RESULTS -Strengthened balance sheet enables focus on both Kanuma ™ and multiple pipeline programs-"
02/09/2015 8-K Entry into a Material Definitive Agreement
02/02/2015 8-K Entry into a Material Definitive Agreement
01/07/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among the Company and Goldman, Sachs & Co. and J.P. Morgan Securities LLC, as representatives of the several underwriters listed on Schedule I thereto",
"Opinion of Ropes & Gray LLP",
"SYNAGEVA BIOPHARMA ANNOUNCES A 2.5 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK",
"SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK",
"SYNAGEVA BIOPHARMA ANNOUNCES NEW PIPELINE PROGRAMS AND OTHER COMPANY PROGRESS"
10/30/2014 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
09/22/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, effective as of September 22, 2014, between Synageva BioPharma Corp. and Robert Bazemore",
"SYNAGEVA BIOPHARMA APPOINTS ROBERT BAZEMORE AS CHIEF OPERATING OFFICER -Focus on Commercial Readiness and Global Operations-"
09/09/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/30/2014 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
06/30/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities Conference Call and Webcast to be Held Today at 4:30 p.m. EDT"
06/09/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Synageva BioPharma Corp. 2014 Equity Incentive Plan"
05/15/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Steve Mahoney, Senior Vice President and Chief Legal Officer"
04/30/2014 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
03/06/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among the Company and Goldman, Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto",
"Opinion of Ropes & Gray LLP",
"SYNAGEVA BIOPHARMA™ ANNOUNCES A 2.00 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK",
"SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK"
03/03/2014 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS"
02/26/2014 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/09/2013 8-K Entry into a Material Definitive Agreement
10/29/2013 8-K Form 8-K - Current report
10/24/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/05/2013 8-K Quarterly results, Appointed COO
Docs: "Employment Agreement, effective as of August 12, 2013, between Synageva BioPharma, Corp. and Alicia Secor",
"SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS AND ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER"
06/10/2013 8-K Submission of Matters to a Vote of Security Holders
05/07/2013 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS"
03/11/2013 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA™ REPORTS 2012 FULL YEAR FINANCIAL RESULTS"
01/22/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
01/04/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among the Company, Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC as representatives of the several underwriters listed on Schedule I thereto",
"Opinion of Ropes & Gray LLP",
"SYNAGEVA BIOPHARMA ANNOUNCES $80 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK",
"SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK"
12/17/2012 8-K Form 8-K - Current report
08/02/2012 8-K Quarterly results
Docs: "SYNAGEVA BIOPHARMA REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS"
07/10/2012 8-K Form 8-K - Current report
07/06/2012 8-K Financial Statements and Exhibits
Docs: "Consent of Ernst & Young LLP",
"Audited Financial Statements of Trimeris Balance Sheets as of December 31, 2010 and 2009 Statements of Operations for the Years Ended December 31, 2010 and 2009 Statements of Stockholder's Equity for the Years Ended December 31, 2010 and 2009 Statements of Cash Flows for the Years Ended December 31, 2010 and 2009 Notes to the Audited Financial Statements",
"Unaudited Condensed Financial Statements of Trimeris Condensed Balance Sheets as of September 30, 2011 and December 31, 2010 Condensed Statements of Operations for the Three-Month and Nine-Month Periods Ended September 30, 2011 and 2010 Condensed Statements of Cash Flow for the Nine Months Ended September 30, 2011 and 2010 Notes to the Unaudited Condensed Financial Statements",
"Unaudited Pro Forma Condensed Combined Statement of Operations of Synageva BioPharma Corp. Statement of Operations for the Year Ended December 31, 2011 Notes to the Unaudited Statement of Operations"
06/28/2012 8-K Form 8-K - Current report
06/25/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "SYNAGEVA BIOPHARMA ANNOUNCES SBC-102 DATA AT UPCOMING SSIEM MEETING - SBC-102 continues to improve disease-related parameters in adults with late onset LAL Deficiency -"
03/15/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy